Neuronetics, Inc. STIM
1.43 USD -0.19 (-11.73%)
At closeNov 12, 2026, 7:47 PM EST
1.47 +0.04 +2.80%
After hours · Nov 12, 7:47 PM ET
1.39 Day range 1.61
1.18 52-week range 3.30
- YTD
- +3.62%
- 1 year
- -33.80%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…
globenewswire.com Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…
benzinga.com Neuronetics Announces Credit Agreement Amendments And Public Offering Of Shares; Size Not Disclosed Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook…
globenewswire.com Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…
benzinga.com B. Riley Securities Maintains Buy on Neuronetics, Raises Price Target to $6 B. Riley Securities analyst Madison El-Saadi maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
seekingalpha.com Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
globenewswire.com Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through…
marketbeat.com Neuronetics Q3 Earnings Call Highlights Neuronetics NASDAQ: STIM reported third-quarter 2026 revenue growth, wider gross margin and a return to positive adjusted EBITDA, citing record NeuroStar system sales and continued revenue-cycle…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
zacks.com Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.13 per share a year ago.
benzinga.com Neuronetics Q3 2026 Earnings Call Transcript Neuronetics (NASDAQ:STIM) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Neuronetics Q3 EPS $(0.02) Beats $(0.09) Estimate, Sales $41.962M Beat $40.425M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.09) by 77.78 percent. This is a 84.62 percent increase over losses of $(0.13)…
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$164.000M vs $162.025M Est Neuronetics (NASDAQ:STIM) affirms FY2026 sales outlook from $160.000 million-$164.000 million to $160.000 million-$164.000 million vs $162.025 million estimate.
globenewswire.com Neuronetics Reports Third Quarter 2026 Financial and Operating Results MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…
globenewswire.com Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…
defenseworld.net Neuronetics, Inc. (NASDAQ:STIM) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages Shares of Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, Marketbeat reports. One…- benzinga.com B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5 B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
globenewswire.com NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
seekingalpha.com Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
marketbeat.com Neuronetics Q2 Earnings Call Highlights Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced…
zacks.com Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
benzinga.com Neuronetics Narrows FY2026 Sales Guidance from $160.000M-$166.000M to $160.000M-$164.000M vs $161.125M Est Neuronetics (NASDAQ:STIM) narrows FY2026 sales outlook from $160.000 million-$166.000 million to $160.000 million-$164.000 million vs $161.125 million estimate.
benzinga.com Neuronetics Q2 EPS $(0.05) Beats $(0.13) Estimate, Sales $41.568M Beat $40.175M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15)…
globenewswire.com Neuronetics and Jorey Chernett Announce Shared Vision MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of…
globenewswire.com Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…
globenewswire.com Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery New location expands access to…
globenewswire.com Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…- benzinga.com Neuronetics Appoints Nir Naor CFO, Effective July 23, Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional…
globenewswire.com Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through…
benzinga.com Why Is Neuronetics Stock Soaring Monday? BTIG initiated coverage of Neuronetics Inc. (NASDAQ:STIM) on Monday, noting that the company is entering a pivotal new phase as the psilocybin opportunity takes center stage.
benzinga.com Why Is Neuronetics Stock Soaring Monday? BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock…
- benzinga.com BTIG Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5 BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
seekingalpha.com Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recent developments and their impact on the investment thesis. Key topics include operational progress,…
benzinga.com Neuronetics Collaborates With ANT Neuro To Expand NeuroStar Advanced Therapy System Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…- benzinga.com Full Transcript: Neuronetics Q1 2026 Earnings Call
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$166.000M vs $162.467M Est Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-single digits.For the full year 2026, Neuronetics continues to expect:Total revenue between $160…- benzinga.com Neuronetics Q1 EPS $(0.16) Beats $(0.17) Estimate, Sales $34.454M Beat $34.183M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 23.81 percent increase over losses of $(0.21)…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sales pushes and a slew of bankruptcies.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Neuronetics Initiates Workforce Reduction Impacting Up To 5% Of Employees, Expects ~$200K Restructuring Charges And ~$2.5-$3M Annualized Savings On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort…- benzinga.com Neuronetics CFO Steven E. Pfanstiel To Depart, Effective May 1; Reiterates Q1, FY26 Outlook Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from…
- benzinga.com Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $3 Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $7 to $3.
- benzinga.com Neuronetics Sees FY2026 Sales $160.000M-$166.000M vs $164.167M Est Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million analyst estimate.
- benzinga.com Neuronetics Q4 EPS $(0.10) Beats $(0.11) Estimate, Sales $41.777M Beat $40.667M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 6.54 percent. This is a 70.59 percent increase over losses of $(0.34)…
- benzinga.com Earnings Scheduled For March 17, 2026